Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

NCT05738694 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

298

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Neoadjuvant

Interventions

DRUG: Axitinib plus Toripalimab
PROCEDURE: nephrectomy

Sponsor

ZHOU FANGJIAN

Collaborators

[object Object]